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ABSTRACT 
BIOCHEMICAL AND ENZYMATIC STUDIES OF THE MIDGUT SERINE 
PROTEASE AASPVII FROM THE AEDES AEGYPTI MOSQUITO 
 
by James Nguyen 
The Aedes aegpyti mosquito is an efficient biological vector of four known neglected 
tropical arboviruses: the yellow fever, dengue, chikungunya, and Zika viruses. Since the 
female mosquito can acquire multiple blood meals to complete the gonotrophic cycle, she 
can potentially infect multiple hosts. With the reemergence of these viruses, especially 
due to global warming, it is crucial to slow the spread of the mosquito and the blood-
borne diseases she transmits. The Ae. aegypti mosquito relies heavily on midgut serine 
proteases that digest blood meal proteins to provide nutrients required for the egg laying 
process. The focus of this work is on a late phase midgut serine protease, AaSPVII. 
AaSPVII is of interest due to its potential difference in specificity and functional role in 
the digestion process, despite its sequence similarity to another late phase protease known 
as AaSPVI. By understanding the important role these midgut serine proteases play, we 
could potentially inhibit these proteases and disrupt fecundity. Currently, two different 
expression constructs were produced, one with an N-terminal His6-tag and the other with 
a C-terminal His6-tag. Both constructs have been recombinantly expressed using bacteria, 
but only the C-terminally His6-tagged AaSPVII has been purified and activated 
successfully. This enzyme has comparable steady-state kinetic parameters to previously 
published results, suggesting that we have optimized soluble bacterial expression.
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Chapter I 
 
INTRODUCTION 
 
Domestication and Spread of the Aedes aegypti Mosquito 
 
The biological vector Aedes aegypti mosquito is classified with the subfamily 
Culicinae of the order Diptera.1,2 From a genetic standpoint, Ae. aegypti is the most 
widely studied and medically important species of mosquitoes because of the ease of 
transition from the field to a laboratory setting and the feasibility of controlled mating.2 It 
has become almost certain that the predominant subspecies of Ae. aegypti in Africa was 
the Ae. aegypti formosus, while the subspecies that originated in Africa and dominated 
the subtropical and tropical regions outside of Africa are the domesticated forms known 
as Ae. aegypti.3,4 Ae. aegypti spread to the New World between the fifteenth and 
eighteenth centuries due to the increase in global trade3,5, and their preference for human 
domestication was most certainly due to human modifications of global landscapes 
through movement and trade.5 What may also have contributed to the domesticated 
behavior of these mosquitoes was the extreme harsh landscape of the Sahara 4,000-6,000 
years ago6 and the fact that the only available source of fresh water that can maintain 
breeding colonies was found in human settlements and on ships.3,7 Based on the historical 
data of the emergence of urbanized dengue (a viral infection transmitted by Ae. aegypti), 
the mosquito may have spread to Asia during the late nineteenth century via cargo ships 
and trade.3 
Like all mosquitoes in the Culicidae family, the Ae. aegypti life cycle consists of a 
metamorphic stage from larvae, pupae, to the adult mosquito. The interesting 
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characteristic about these mosquitoes is their eggs, which can be highly resilient and can 
survive through desiccation for several days to up to a year.1,8 Their pupa can also survive 
through desiccation for several hours.1 This particular attribute may have allowed for the 
mosquitoes to be transported to other parts of the world until they were able to find an 
adequate water source to hatch and, as expected, allowed for further spread of specific 
viruses and increased population due to their close proximity to human hosts.1,7 
Blood Feeding Behavior – Spread of Vector-Borne Diseases 
Typically, both male and female mosquitoes require carbohydrates, commonly from 
nectar, as the main energy source to maintain flight and other basic functions. Eventually, 
the female mosquito would be required to imbibe a blood meal to complete the 
gonotrophic cycle.1,9 Unfortunately, because of the Ae. aegypti mosquito’s close 
association to human settlements, this “new” domestic habitat led to a heavy reliance on 
human blood as their new primary energy source for egg production.9 The proximity 
between human and mosquito allowed the mosquitoes to adapt and evolve, thus giving 
them a fitness advantage to respond to certain host cues (such as CO2 release and host 
odors)10 to detect the presence of humans, and as such locate blood and its nutritional 
quality.9,11 This adaptation has also affected the female’s sugar-feeding behavior, which 
unexpectedly reveals that the female mosquitoes seldom feed on nectar in their domestic 
environments, demonstrating that sugar-feeding was facultative.9 This lack of 
carbohydrate feeding was observed as the mosquitoes would mate near humans and be 
found indoors more often, thereby reducing flight demands.9 The anthropophilic behavior 
of the female mosquito has also suggested that she may survive solely on a blood meal by 
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increasing the amount she intakes.12 This will allow for multiple events of blood feeding 
and host-seeking, thereby increasing fecundity and population.9,13 However, because of 
this blood feeding behavior, the Ae. aegypti is an efficient biological vector for the yellow 
fever (YFV), dengue (DENV), chikungunya (CHIKV), and Zika viruses (ZIKV), having 
the ability to carry more than one virus and being able to infect a human host with 
multiple viruses from a single bite.14 Thus, the presence of the Ae. aegypti mosquito 
becomes a critical issue for humid and urbanized human environments.9,13 
One of most recent global concerns around the world is the mosquito-borne flavivirus 
ZIKV.15 ZIKV is the latest culprit on the long list of arboviruses originating in Africa.15 
Like YFV and DENV in the family Flaviviridae, ZIKV are enveloped, single-stranded, 
positive-sense, obligate intracellular RNA viruses. Although ZIKV, YFV, and DENV are 
similar in genomic organizations, ZIKV is fundamentally different in host infectivity and 
how the viruses are spread.15,16 The virus was initially isolated in the Zika forest in 1947 
from the serum of the rhesus monkey.17 The virus was not detected and isolated from 
humans until the 1950s, being reported in Uganda, Tanzania, and Nigeria.18,19 Between 
the 1950s and 1980s, ZIKV was predominately localized in Asian and African countries 
and did not migrate to the Pacific Islands until the early 2000s. During this time, ZIKV 
infection became more rampant, spreading to the Americas and now observed in 
U.S.territories and the U.S.15,20 There have been over 36,000 reported cases in the U.S. 
territories and 200 locally acquired cases in the U.S.20 Thus far, ZIKV has been the only 
flavivirus to be sexually transmitted with 41 confirmed cases in the U.S. (as of February 
2017), which was reported by the Centers for Disease Control and Prevention (CDC).20 
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One major issue with ZIKV is that infected people will typically not have any immediate 
onset of symptoms or will not show any symptoms at all. If symptoms do arise, they may 
last anywhere from several days to a week, with a likelihood of being protected from 
subsequent ZFV infections. However, the duration of the immunity is still unknown.15 
Common symptoms include fever, rash, joint pain, conjunctivitis, muscle pain, and 
headaches. The most striking congenital abnormality occurs within pregnant women and 
has been shown to have a direct association with microcephaly of the fetus.15,21 This type 
of manifestation was linked to a 2015 Zika outbreak in Brazil where microcephaly was 
observed 20 times more than usual.15 There have been rare cases of adults dying with 
ZIKV, but the exact contributions from the virus, if any, to these deaths are still relatively 
unknown.22  
Another important and dangerous arthropod-borne viral infection that affects humans 
is DENV. It has been estimated that 2.5 billion people around the world are currently at 
risk of contracting dengue, with approximately 40% of those people living in tropical and 
sub-tropical urbanized areas, such as the Pacific and the Americas.23,24  Unlike the other 
flaviviruses that are carried by the Ae. aegypti mosquito, DENV is known to have four 
serotypes (DENV-1, DENV-2, DENV-3, DENV-4)23,24, and recently a fifth serotype 
(DENV-5) has been identified.25 Each serotype shares approximately 65% genetic 
similarity and produces nearly undistinguishable syndromes and circulates in the same 
ecological niche.23 Infection against one serotype will provide a long-lasting immunity 
against only that serotype, as a secondary heterotypic infection has been shown to lead to 
more severe symptoms.23,24 The onset of this disease can lead from minor to severe fever, 
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headaches, muscle and joint pains, nausea, vomiting, swollen glands, and rashes. 
Secondary infection can increase the risk of dengue hemorrhagic fever, which can cause 
severe abdominal pains, bleeding gums, and blood in vomit.23,24 Recent published data 
have also hypothesized that DENV may drive antibody-dependent enhancement (ADE) 
of infection with ZIKV, as DENV specific antibodies could bind to the ZIKV but are 
unable to neutralize and defend against the virus.26 This is of concern because the results 
reported by Dejnirattisai et al. (2016) and Priyamvada et al. (2016) implicated that 
antibodies that were present to neutralize DENV were cross-reacting and promoting ADE 
of ZIKV infection.26,27 This type of ADE of infection in children was also hypothesized 
with the recently licensed CYC-TDV vaccine26, also known as Dengvaxia as created by 
Sanofi Pasteur which is currently in use in Brazil, Costa Rica, El Salvador, Mexico, 
Paraguay, and the Philippines.28 Vaccination of DENV naïve patients experienced a 
greater rate of hospitalization than patients that were initially infected. This case 
observation led to the hypothesis that vaccination of seronegative patients was poorly 
protected from the pathogen despite developing enhanced antibodies for DENV1-4 and 
had a higher risk of infection.26,28 Other vaccines are being developed to combat DENV 
serotypes 1-4, with the company Takeda currently in phase II and Butantan in phase III 
clinical trials.29 
Yellow fever is a flavivirus infection caused by YFV and found mainly in sub-Sahara 
Africa and tropical South America where one billion people in 46 countries are at risk of 
infection30 The disease was greatly feared until the development of a live attenuated 
vaccine by Max Theiler and associates in the 1930s.30 Although, the vaccine helped 
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combat the virus considerably in the following decades, reports for yellow fever have 
been substantially underreported due to nonspecific symptoms between febrile illnesses 
and the limitations in surveillance and healthcare systems in the affected areas.31 About 
180,000 people are infected and 78,000 die every year despite the availability of a 
working vaccine.30,31 This fact is attributed to the decline of mass vaccination after the 
1960s, which may have allowed for the resurgence of the YFV.30,31 Yellow fever 
symptoms are separated by two phases: the acute and toxic phases. A period of 3-6 days 
after infection, fever, muscle pain, headache, shivers, loss of appetite, nausea, and 
vomiting can occur. After an additional 3-4 days, many people tend to improve and the 
illness dissipates. However, approximately 15% of the infected people can enter the toxic 
phase, which can lead to stronger fevers, jaundice, and bleeding.24 
The CHIKV is a re-emerging alphavirus that belongs to the Togaviridae family, 
which was observed in 2004 in Kenya.32 After this, the virus began to spread to other 
novel locations, such as the South-East Asia region, including India where over one 
million cases were reported in 2006.24,33 CHIKV is comprised of an enveloped, positive 
single-stranded RNA virus, which upon infection leads to a rapid onset of symptoms. 
Common symptoms are very similar to the previously described Zika, dengue, and 
Yellow fever viruses, except that, in severe cases, chikungunya fever can cause long-
lasting joint pains that may last for several weeks or years.24,33 There is currently no 
treatment available for chikungunya which continues to be a growing problem along with 
the other viruses. 
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The Nature of the Problem  
There has been an increasing presence of arboviruses in the United States, mainly due 
to the appearance of the Ae. aegypti and Ae. albopictus mosquitoes, which are the 
principal vectors of the tropical diseases associated with YFV, DENV, CHIKV, and 
ZIKV viral infections.34 The viruses are transmitted through the saliva when the female 
mosquito acquires a blood meal. The blood meal is needed for the female mosquito to 
obtain the necessary nutrients and energy to complete the gonotrophic cycle.35,36 Global 
warming and the blood feeding behavior of these mosquitoes have contributed to 
facilitating the transmission and resurgence of the DENV and YFV in tropical and 
subtropical regions31,37-39 and the recent rapid spread of CHIKV and ZIKV across the 
globe.40 As of now, a vaccine is only available to combat the yellow fever virus30 with a 
potential vaccine against dengue remaining elusive due to disappointing results from 
clinical trials of a leading candidate known as Dengvaxia.28 Therefore, the only option to 
combat these diseases and the mosquito is through vector control. However, mosquito 
control methods have specific flaws that lead to increasing resistance due to overuse of 
insecticides and have very limited specificity, killing off other important insects (such as 
butterflies and bees). Also, removal of standing water that provides ideal breeding sites 
for the mosquito may be impractical for regions with rainy seasons.41,42 Currently, a new 
specific vector control strategy against the Ae. aegypti mosquito utilizes male transgenic 
mosquitoes that will pass on a lethal gene to the offspring, killing the progeny before they 
can reach adulthood.43 However, due to the varying degree of arbovirus density in 
different regions of the world and public resistance to field trials, it becomes extremely 
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difficult to release these engineered mosquitoes into the wild globally.44-46 All of these 
factors make it extremely crucial to further study the Ae. aegypti mosquito and its vector-
borne diseases and to investigate potential novel techniques to slow or reduce the spread 
of the mosquitoes and pathogens. 
Digestion of Blood Meal by Regulated Midgut Proteases  
The midgut of the mosquito is the main site for blood meal protein digestion and 
subsequent extraction of any essential nutrients and adsorption. The midgut also acts as 
the site where viruses can infect the vector, and once infected the mosquito can transmit 
the virus to vertebrate human hosts.47 Once the female mosquito imbibes the blood meal, 
an extracellular layer produced by midgut epithelial cells is formed around the ingested 
blood. This peritrophic matrix allows for the retention of the blood meal until it can be 
fully degraded for its nutrients.48 The peritrophic matrix is composed of chitin fibrils and 
proteoglycans that act to control the traffic of molecules between the midgut epithelial 
and lumen and to protect against any type of abrasion and toxic products that may derive 
from blood digestion.48 The typical body weight of the mosquito is around two 
milligrams, and she can acquire more than her own body weight in blood.47 This can 
result from a single blood meal or from multiple blood feedings.9,13,47 For this reason, she 
is under immense stress, and the midgut must respond accordingly by releasing 
proteolytic enzymes to quickly digest and detoxify the blood meal.47 The digestive 
enzymes are produced in the midgut and have evolved to be a specialized system to 
efficiently cleave the protein-rich blood meal47 within two days.49 
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When the female Ae. aegypti mosquito obtains a blood meal, this initiates the release 
of proteolytic enzymes in the midgut aiding in the degradation of blood meal proteins 
into peptides and amino acids that can be used for carbohydrate, lipid, and yolk protein 
synthesis, fueling mosquito functionality and egg production.36,50 The expressed digestive 
enzymes consist of endopeptidases, which are comprised of trypsin-51,52 and 
chymotrypsin-like53,54 serine proteases, and exopeptidases, which are comprised of 
aminopeptidases55 and carboxypetidases.56,57 Although many different proteolytic 
enzymes are present, published work by Felix et al. in 1991 revealed a two-phase process 
of midgut trypsin-like activity in the Ae. aegypti mosquito58, suggesting that trypsin may 
be the main proteolytic enzyme responsible for blood meal digestion.58,59 As seen in 
Figure 1, biphasic trypsin-like activity begins with an initial early phase almost 
immediately after a blood meal to 6 hours post blood meal (PBM), followed by the late 
phase starting at 12-18 hours PBM, reaching maximal activity at the 30th hour PBM.59  
10 
 
 
Figure 1. Total BApNA activity in individual mosquito midguts as determined by 
quantitative enzyme kinetic analysis using steady-state assumptions. A) Total midgut 
extract. B) Suppression of AaSPVI only. C) Suppression of AaET only. Reproduced from 
Insect Biochemistry and Molecular, 39/12, Isoe, J., Rascón, A.A., Kunz, S., Miesfeld, 
R.L., Molecular genetic analysis of midgut serine proteases in Aedes aegpyti, 903-912, 
2009, with permission from Elsevier. 
The observed biphasic manner of midgut trypsin-like activity was suggested to have 
specific proteases induced at specific hours.58 During the first 6 hours PBM, a protease 
known as early trypsin (AaET) was found to be abundantly expressed.51,60 Interestingly, 
high levels of un-translated AaET mRNA transcripts are already present in the midgut 
epithelial cells of the adult female mosquito before a blood meal and are not translated to 
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protein until a blood meal is ingested.61 Two late serine endopeptidases known as late 
trypsin (AaLT) and 5GI (later renamed AaSPVI) were also characterized around the same 
time as early trypsin. They were shown to be strongly expressed at the 24th hour PBM, 
insinuating that they may be essential during late phase digestion.51,52,62 In the 1990s, 
AaET was thought to activate AaLT through an unknown signal transduction system. For 
this experiment, soybean trypsin inhibitor (STI) was added to an artificial blood meal and 
fed to mosquitoes resulting in inhibition of AaET protease activity, which led to the loss 
of AaLT protease activity.63 This was reevaluated in 2006 when Lu and associates 
discovered that the original STI used in their experiments was contaminated with 
potential toxins leading to the aforementioned results. Therefore, Lu et al. (2006) then 
repeated the feeding experiments using a variety of specific trypsin inhibitors that did 
inhibit early trypsin activity, but had no effect on late trypsin activity. These results were 
unexpected as it contradicted the original results obtained with the original STI.64 To 
ensure that the inhibitors were not affecting other metabolic and transcriptional processes, 
the researchers suppressed AaET mRNA translation using RNA interference (RNAi) 
technology. At the time, RNAi was successfully used in initial studies by Blandin and 
associates in 2002 studying the function of the Defensin gene in Anopheles gambiae65. 
The method was optimized for Ae. aegypti to reduce AaET levels, which led to no 
significant effects on late trypsin activity.64 This result, combined with the inhibition 
study provided evidence that AaET activity was not necessary for late phase enzyme 
activity.64 
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Considering the high abundance of AaET51,60,61, AaLT52,62, and AaSPVI51, and the 
discovery of an additional highly induced late phase protease known as AaSPVII59,66, 
Isoe and associates investigated the important impacts these four highly expressed midgut 
serine proteases have on blood meal protein digestion and egg development.59 However, 
before these studies were conducted, trypsin-like activity was measured in individual Ae. 
aegypti mosquito midguts using Nα-benzoyl-L-arginine-4-nitroanilide (BApNA), a 
common chromogenic trypsin substrate analog. As seen in figure 1C, AaET knockdown 
confirmed the results from Lu et al. (2006) (described above), which did not affect late 
phase midgut trypsin-like activity.59 In fact, the majority of midgut late phase BApNA 
activity was shown to be from AaSPVI (Figure 1B), while knockdown of AaSPVII and 
AaLT had no significant effect on overall activity.59 However, as shown in Table 1, the 
suppression of AaSPVII and AaLT had a greater effect on the amount of eggs laid, 
despite AaSPVI’s prominent late phase BApNA activity.59 These results are interesting 
because AaSPVII is shown to be homologous to AaSPVI66 (68% sequence identity, 
National Center for Biotechnology Information (NCBI) database), and so similar activity 
should have been observed, but these studies suggest that the enzymes may be playing 
different functional roles in the blood meal digestion process.59 In addition, research 
studies by Rascón and associates have shown that AaSPVII has double the turnover 
number (kcat) and higher specific activity towards BApNA than AaSPVI in vitro
67, which 
may indicate differences in substrate specificity in vivo. However, as seen in Figure 2 and 
Table 1, by inhibiting AaSPVII and the other midgut serine proteases, midgut blood meal 
protein digestion may be prevented, and thus eliminate the necessary nutrients needed for 
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egg development.59 Therefore, it is essential to further characterize these proteolytic 
enzymes and verify if targeting them can aid in reducing the mosquito population as a 
potential vector control strategy.  
 
Figure 2. The effects of dsRNA injection or diluted protein bloodmeal on ovary 
development. A) dsRNA for each protease were designed, synthesized, and injected into 
female mosquitoes prior to blood feeding. Mix represented the combination of AaSPVI, 
AaSPVII, and AaLT. B) Blood was diluted from 20 to 80% with feeding buffer and fed 
to uninjected mosquitoes. Reprinted from Insect Biochemistry and Molecular Biology, 
39/12, Isoe, J., Rascón, A.A., Kunz, S., Miesfeld, R.L., Molecular genetic analysis of 
midgut serine proteases in Aedes aegpyti, 903-912, 2009, with permission from Elsevier. 
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Table 1. Summary of Fecundity Data from Individual dsRNA-Injected Mosquitoes. 
 
N: Number of mosquitoes tested. 
***Indicates egg numbers significantly different from dsRNA-Fluc injected mosquitoes (P < 0.001 in all cases). 
Mix refers to injection with a mixture of AaSPVI, AaSPVII, and AaLT dsRNA using 400 ng f each. 
 
Reproduced from Insect Biochemistry and Molecular Biology, 39/12, Isoe, J., Rascón, 
A.A., Kunz, S., Miesfeld, R.L., Molecular genetic analysis of midgut serine proteases in 
Aedes aegpyti, 903-912, 2009, with permission from Elsevier. 
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Chapter II 
Initial Biochemical Characterization of N-terminally His6-tagged AaSPVII 
Introduction 
The ingestion of a blood meal by the female Ae. aegypti mosquito releases digestive 
enzymes known as exo- and endopeptidases.66,68 The abundantly expressed midgut serine 
proteases released PBM are endopeptidases, more specifically trypsin-like serine 
proteases, which account for the majority of the digestion of blood meal proteins.58 
Trypsin, in general, has been known to be one of the most important, extensively studied 
enzymes for its role in food protein hydrolysis and its ability to autocatalyze its zymogen 
form (trypsinogen) to the active form and activate other digestive proteolytic enzymes in 
both vertebrates and invertebrates.68-70  
Serine proteases are so named because proteolytic activity depends on a catalytic 
serine residue.69 When catalysis begins, the serine at the active site becomes deprotonated 
by histidine, becoming a nucleophile and attacking the carbonyl of a peptide substrate 
forming a tetrahedral intermediate.69,70 This serine deprotonation by histidine and 
histidine stabilization by aspartate are part of a charge relay system known as the 
catalytic triad (Ser-His-Asp).69,70 The specificity of each enzyme is due to the amino acid 
in the substrate pocket. With trypsin, there is an aspartate residue in the substrate pocket, 
which stabilizes the positively charged lysine and arginine amino acid residues, leading 
to the specificity and cleavage of the peptide bonds on the carboxyl side of these amino 
acids. Chymotrypsin prefers peptide bonds associated with the carboxyl side of the large 
hydrophobic, aromatic amino acids, tyrosine, tryptophan, and phenylalanine.69,70 In 
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contrast, serine collagenases have a serine residue in the binding pocket, therefore 
preferring different specificities than that of trypsin and chymotrypsin.67 
Initial biochemical studies of recombinant AaET, AaSPVI, and AaSPVII show that 
they exhibit trypsin-like activity when using BApNA as a substrate (Table 2).67 AaET 
was shown to have the highest specific activity towards BApNA, having 5-fold more 
activity than the other three abundant midgut proteases, and AaET was about 1.5-fold 
higher than the bovine trypsin control. AaET, AaSPVI, and AaSPVII have been classified 
as classical trypsin enzymes59,66,67; however, their exact specificity and catalytic 
mechanism are still unknown. As mentioned above, AaSPVI and AaSPVII are 
homologous to each other (68% sequence identity), but AaSPVII was shown to cleave 
BApNA more efficiently than AaSPVI despite their amino acid similarities.67 This was 
interesting because, as seen in Figure 1, it was previously shown that knockdown of 
AaSPVI expression reduced late-phase trypsin-like activity by ~78%59 despite its low 
specific activity and turnover number.67 This raises the question as to why AaSPVII was 
shown to have higher specific activity than AaSPVI, but did not contribute to much of the 
late phase BApNA cleavage and contributed significantly to the overall fecundity in 
blood fed mosquitoes.59,67 To attempt to answer this question, further biochemical studies 
using bacterial recombinant and protein expression techniques must be done on the 
protease to investigate its structure and function. 
Bacterial recombinant technology has revolutionized biochemistry because, by 
applying the right combination of bacterial expression vectors and bacterial expression 
strains, one can achieve high-level production of recombinant proteins that are needed for 
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in vitro biochemical characterization.71 Rascón and associates attempted to first purify the 
full-length zymogen forms of AaET, AaSPVI, AaSPVII, and AaLT, including the signal 
peptide (leader) sequence.67 Unfortunately, the low levels of bacterial expression, 
insoluble protein, and purification of recombinant forms of these proteases did not yield 
enough products to perform biochemical studies.67 There may have been two main 
reasons for the high level of insoluble expression of the proteins. First, the presence of 
the leader sequence may have affected the overall efficiency of the expression. In Figure 
3, the full-length gene with the leader sequence is present before the propeptide region, 
the region that needs to be cleaved to form the mature protease.67,69  
 
Figure 3. Amino acid sequences of the wild-type zymogen and the engineered 
heterologous enterokinase artificial propeptide region (Mek) forms of the enzymes. 
Reprinted from Biomed Central Biochemistry, 12/43, Rascón, A.A., Gearin, J., Isoe, J., 
Miesfeld, R.L., In vitro activation and enzyme kinetics analysis of recombinant midgut 
serine proteases from dengue vector mosquito Aedes aegypti, 2011, with permission from 
BioMed Central Ltd. 
 
Although the leader sequence plays a key role in targeting and membrane insertion of 
secretory and membrane proteins in both prokaryotes and eukaryotes, the presence of the 
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signal peptide during recombinant protein expression has been shown to lead to 
thermodynamic destabilization, which reduces the activity of the desired protein and 
increases aggregation propensity.72 In addition, results published from Promdonkoy et al. 
(2004) showed improved expression levels of mosquitocidal toxin 1 after removal of the 
putative leader sequence.73 For the Rascón et al. (2011) studies, the leader sequence was 
kept for AaET, AaSPVI, AaSPVII, and AaLT, which may have contributed to the low 
expression levels.67 As an alternative, Rascón and associates engineered a heterologous 
enterokinase cleavage site, which has the designated DDDDK sequence. As seen in 
Figure 3, the enterokinase (EK) cleavage was engineered to allow for the activation of the 
desired protease by using commercially available enterokinase to cleave the EK 
propeptide site, forming the mature protease, but also to help improve expression levels 
by removing the leader sequence.67 However, this approach still resulted in insoluble 
expression, leading to the second main reason why high levels of insoluble protein 
expression were observed. In the paper, Rascón et al. described using Novagen Rosetta 2 
(DE3) and BL21 (DE3) E. coli bacterial expression systems. The BL21 (DE3) E. coli 
strain is a common bacterial T7 expression system that works by using a synthetic 
inducer isopropyl-β-D-thiogalactopyranoside (IPTG) to activate the expression of genes 
cloned into pET vectors, while the Rosetta 2 (DE3) is a BL21 (DE3) derivative that aims 
to increase eukaryotic protein production by supplying specific rare codons that are not 
commonly found in bacteria71. Although this may be the case, Rosetta (DE3) strains in 
general have been shown to both improve levels of protein production and protein 
insolubility.71 The reason for expression of insoluble protein using these cells has to do 
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with the fact that the bacterial cytoplasm is a reducing environment, which is the site 
where recombinant protein expression takes place.71 This is important to understand 
because proteases have been shown to rely on proper disulfide bond formation to 
properly fold and be biologically active.74 By using these cells, proper disulfide formation 
is not possible due to the reducing cytoplasm of wild-type E. coli, which can lead to the 
expression of insoluble, unfolded proteins and aggregates known as inclusion bodies.74 
With high levels of inclusion bodies, denaturing/refolding strategies must be considered 
to obtain soluble proteins.75 Refolding is not straightforward and may require an 
extensive trial-and-error approach with various reagents needed for proper solubilization 
and refolding. Denaturation occurs by using specific agents (such as guanidine HCl or 
urea) that can solubilize the desired inclusion bodies efficiently. The rate at which the 
protein can refold depends on the method to reduce the denaturant concentration and the 
solvent conditions used.75 During this rigorous process, misfolding and aggregation may 
also occur, which can lead to varying yields of soluble protein.75 
Due to the challenges presented, several changes can be made. To start, primer design 
and DNA cloning can be utilized to remove the hydrophobic leader sequence from the 
desired protease gene. By analyzing the full-length AaSPVII amino acid sequence using 
the SignalP 4.1 Server, we can identify the location of the signal peptide cleavage site 
sequence and develop specific primers to remove the leader sequence. The leaderless 
protease gene can then be cloned into the pET28a vector expression system to utilize the 
poly His6-tag feature for purification. Once cloned, AaSPVII can be expressed in BL21 
(DE3) derivatives known as T7 SHuffle competent cells (New England BioLabs). These 
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E. coli strains carry mutations to favor an oxidizing cytoplasm and disulfide bond 
isomerase, DsbC, that assist in disulfide bond formation.76 This chapter will discuss the 
efforts to apply these conditions to express the late-phase midgut serine protease 
AaSPVII in bacteria and the approach taken for obtaining purified, soluble protein. In 
addition, site-directed mutagenesis will also be discussed as it has been hypothesized that 
the Ae. aegpyti midgut serine proteases may be autocatalytic in the absence of the 
enterokinase cleavage site.51 Enterokinase serves to regulate the activation of trypsin69, 
but the putative insect trypsinogens lack this region, which may also explain why 
enteropeptidases have not been found in mosquitoes.51 We aimed to perform point 
mutations at the arginine residue of the predicted propeptide cleavage site (see Figure 3) 
and at the serine of the active site of AaSPVII to further elucidate the activation process 
of this protease if it is indeed autocatalytic. 
Table 2. Steady-State Kinetic Parameters of Mosquito Proteases and Bovine Trypsin 
using BApNA as a Substrate. 
 
Reprinted from Biomed Central Biochemistry, 12/43, Rascón, A.A., Gearin, J., Isoe, J., 
Miesfeld, R.L., In vitro activation and enzyme kinetics analysis of recombinant midgut 
serine proteases from dengue vector mosquito Aedes aegypti, 2011, with permission from 
BioMed Central Ltd. 
 
21 
 
Methods 
Preparation of Late-Phase Midgut Serine Protease AaSPVII Plasmid Construct  
The leader (signal peptide) sequence cleavage site was identified using SignalP 4.1 
Server and ExPASy – Translate Tool. The leader sequence was removed, and 
identification of the proper zymogen sequence was determined to design the correct 5’-
end (forward) primer and 3’-end (reverse) primer. Restriction cleavage sites of NdeI 
(CATATG) and HindIII (AAGCTT) were included to form complementary sticky ends 
for proper cloning into the pET28a vector. A poly-A tail was also added for restriction 
enzyme cleaving efficiency. A double stop codon (TAATAA) was introduced as part of 
the HindIII restriction site for the reverse primer. The melting temperatures (Tm) of the 
designed primers were determined using NetPrimer from Premier Biosoft 
(http://www.premierbiosoft.com/netprimer/), as listed in Table 3.  
Table 3. Primers Designed and used for PCR Amplification and Cloning of No Leader 
Wild-Type AaSPVII Zymogen. Primers were purchased from Elim Biopharmaceuticals, 
Inc. 
 Protease  Primer                      Primer Sequence                            Tm (°C) 
AaSPVII -
Zymogen 
AaSPVII-
Zym-pET-
Fwd 
5’ – AAAAACATATGCTATCAACCGGATTCCATCCGC – 3’ 65.4 
AaSPVII -
Zymogen 
AaSPVII-
Zym-pET-
Rev 
5’– AAAAAAAGCTTATTAAACTCCACTGACTTCGGCCA– 3’ 63.7 
Poly-A tail used is in BOLD. 
Restriction sites used for cloning of the genes of interest are underlined. 
Start and double stop codons are italicized. 
Annealing temperature calculated using NetPrimer. 
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PCR amplification was performed as described in the Promega GoTaq Green Master 
Mix (Cat. # M7122) protocol using the designed forward and reverse primers purchased 
from Elim Biopharmaceuticals, Inc. The DNA template used to amplify the No Leader 
AaSPVII gene of interest was that of the full-length AaSPVII gene cloned into the 
pET29a vector (AaSPVII Z/pET29a). No leader AaSPVII Zymogen was amplified using 
the Eppendorf Mastercycler Gradient thermocycler. The thermocycler was set at 95 °C 
for 5 minutes (initial denaturation), 25 cycles at 95 °C for 20 seconds (denaturation), 
60°C for 20 seconds (annealing), 72 °C for 20 seconds (elongation), and then a final 
elongation at 72 °C for 5 minutes. An amount of 1000 ng of pET28a vector (Novagen 
Cat. #6986-3) and the amplicon were digested separately in 1X FastDigest buffer 
(ThermoScientific), 1 μl NdeI (ThermoScientific Cat. #FD0584), and 1uL HindIII 
(ThermoScientific Cat. #FD0505) restriction enzymes at 37 °C for 60 minutes. The 
enzymes were inactivated by incubating the reaction tubes at 90 °C for 10 minutes, 
followed by a 5-minute ice incubation. The digested vector was then dephosphorylated 
with thermosensitive alkaline phosphatase (TSAP) (Promega Cat. # M9910) to prevent 
the vector from ligating. PCR product, digested/dephosphorylated vector, and GeneRuler 
1 kb DNA Ladder (ThermoScientific, #SM0311) were run on a 1% agarose gel using 1X 
TAE buffer. The desired bands were excised and extracted by following the protocol 
described in the QiaQuick Gel Extraction Kit (Qiagen Cat. # 28707). Both the digested 
amplicon and the dephosphorylated vector were concentrated by ethanol precipitation and 
ligated in 1X T4 DNA ligase buffer (New England BioLabs Cat. #M0202), 18 μl Milli-Q 
water, and 1 μl T4 DNA ligase (New England BioLabs Cat. #M0202). The ligation 
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reaction was incubated at room temperature for 30 min. Ligated AaSPVII (No Leader) 
zymogen/pET28a was transformed into NEB 10-β competent E. coli cells (New England 
BioLabs # C3019) as described in the High Efficiency Transformation Protocol with the 
following modifications. From the AaSPVII (No Leader) zymogen/pET28a ligation 
reaction, 10 μl was added into separate transformation tubes containing the bacterial 
cells, and transformation protocol followed. For the recovery phase, SOC media was 
added and the reaction was incubated in a Lab-line Orbit Envirion Shaker at 37 °C (220 
rpm) for 60 minutes. The transformation tubes were centrifuged for one minute at full 
speed and then 950 μl of the supernatant was discarded. The pelleted cells were re-
suspended with the remaining 50 μl and the whole volume was plated on to pre-warmed 
luria broth (LB) agar plates supplemented with kanamycin (30 μg/ml). Once colonies 
were observed, overnight cultures were set and placed in 37 °C shaker overnight (220 
rpm). Isolation of the plasmid was done by following the QIAprep Spin Miniprep Kit 
(Qiagen, Cat # 27106) protocol, with the exception of the elution step. Plasmid DNA was 
eluted using 55 μl MilliQ water. The concentration of the AaSPVII (No Leader) zymogen 
pET28a plasmid was determined using the ND 1000 Spectrophotometer Nanodrop. All 
plasmid samples were sent to Elim Biopharmaceuticals, Inc. for DNA sequencing and 
then analyzed and confirmed by using the Basic Local Alignment Search Tool (BLAST) 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi), Clustal Omega <Multiple Sequence Alignment 
< EMBL-EBI (http://www.ebi.ac.uk/Tools/msa/clustalo/), and ExPASy – Translate Tool 
(http://web.expasy.org/translate/). 
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Small-Scale Bacterial Overexpression Using BL21 (DE3) and T7 Shuffle Competent 
Cells and In Vitro Spectrophotometric BApNA Assay 
 
The AaSPVII (No Leader) Z/pET28a plasmid construct was transformed into the 
BL21 (DE3) bacterial expression system as described in the BL21 Competent Cells 
(BioLine Cat. # BIO-85032) protocol.  However, rather than plating the entire volume of 
transformant (as described above for NEB 10-β), only 10 μl of the resuspended pellet was 
used. The overexpression of the protein of interest was done by selecting a single colony 
from the transformation plate and by growing overnight in 5 mL LB medium 
supplemented with 30 μg/ml kanamycin (37 °C, 220 rpm). From the overnight culture, 
the initial volume of cell culture was calculated to initially begin at an OD600 of 0.05 in an 
autoclaved 125 mL Erlenmeyer flask with 50 mL LB + kanamycin (30 μg/ml) and set in 
a 37 °C shaker at 220 rpm. At OD600 ~0.5-0.8, the cell culture was induced with 0.1 mM 
isopropyl-β-D-thiogalactopyranoside (IPTG) and grown for 4 hours and 1 mL samples 
were collected at different time points.      
The AaSPVII Z/pET28a plasmid construct was also transformed into SHuffle T7 
Express Competent E. Coli High Efficiency Transformation cells (New England BioLabs 
Cat. #C3029), as described above for BL21 (DE3) cells. Overnight cultures were 
prepared in LB with kanamycin and set in a 30 °C shaker (250 rpm) overnight. The 
bacterial growth experiment was repeated as above, except the cells were grown in 
terrific broth (TB) at 30 °C (250 rpm) until an OD600 ~0.5-0.8, and before inducing with 
0.1 mM IPTG, the temperature was lowered to 23 °C. Cells were grown for 28 hours and 
1 mL samples collected at different time points. 
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For SDS-PAGE analysis, all time points were resuspended in 20mM Tris-HCl, pH 
7.2, and sonicated at 20% amplification for 10 seconds each (total of three cycles) on ice. 
A sample was collected (total protein sample) before centrifugation and after 
centrifugation at 13,000 rpm (4 °C) a soluble protein sample was collected. All protein 
samples were prepared for electrophoresis with 6x SDS-PAGE sample buffer and 
denatured at 95°C for 4 minutes. SDS-PAGE was done using Novex NuPAGE SDS-
PAGE 4-12% Bis-Tris gels (Invitrogen, Cat. #NP0321BOX), prestained protein ladder 
(ThermoScientific PageRuler Cat. # 26616), and 1X NuPAGE MES running buffer 
(Invitrogen Cat. #NP0002). After running the gels, they were stained with InVision His-
Tag In-Gel stain (Life Technologies Cat. #LC6030) and SimplyBlue Stain (Life 
Technologies, Cat. # LC6060). The BL21 (DE3) expressed proteins were only blue 
stained as per the manufacturer’s protocol.  
The synthetic chromogenic substrate BApNA (Acros Organics, Cat. # AC227740010) 
was used to test for trypsin-like activity. The time point samples collected from the 
AaSPVII expressed in T7 Shuffle cells were used.  A typical BApNA master mix 
reaction can be seen in Table 4. Reactions were initiated with 20 μL of the AaSPVII 
crude lysate, and the absorbance at 405 nm was monitored using the Hewlett Packard 
(HP) 5452A Diode Array spectrophotometer. Initial reaction rates of each time point 
were monitored for 10 minutes. 
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Table 4. Typical BApNA Master and Reaction Mixture used for Activity Assays. 
BApNA was dissolved in DMSO. 
 
Large-scale Overexpression in T7 SHuffle and Purification 
 
The AaSPVII (No Leader) Z/pET28a construct was transformed in T7 SHuffle 
bacterial cells (New England BioLabs) and overnight cultures set, as above. However, a 
larger volume was used to set the overnight cultures (75 mL LB + kanamycin (30 
μg/ml)). The overnight cultures were incubated in a ThermoScientific MaxQ 4000 shaker 
at 30 °C and set at 250 rpm overnight. The bacterial growth expression was done as 
described above, but rather than a single 50 mL growth, 6 x 0.5 L of TB + kanamycin (30 
μg/ml) in autoclaved 1 L Erlenmeyer flasks were used. The cultures were induced and 
grown for 5 hours. Bacterial cells were harvested by centrifugation at 6000 rpm (8 °C) for 
10 minutes using the IEC B-22M Programmable Centrifuge. Pellets were then flash 
frozen in liquid nitrogen and stored at -80 °C until needed. 
The AaSPVII (No Leader) Zymogen enzyme was highly expressed in soluble form in 
the conditions described (see Results section for more information). For purification, 7 to 
10 g of the collected cell paste was used. Cell paste was lysed by pulse sonication at 30% 
BApNA 
Activity 
     
 20 mM 10 mM 1 mM   
Sample (μl) 
1 M Tris-HCl, 
pH 7.2 (μl) 1 M CaCl2 (μl) 
138 mM 
BApNA (μl) ddH2O (μl) 
Total Volume 
(mL) 
20 20 10 7.2 942.8 1 
400 400 200 144.9 18855.1 20 
For Master Mix, 
combine water, 
Tris, and CaCl2 
only 
     
For a single 
reaction: 1 mL 
    
Master Mix (μl) Sample (μl) Total Volume 
(mL) 
   
980 20 1    
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amplification for 15 minutes on ice in buffer containing 20 mM Tris-HCl, pH 7.2 + 250 
mM NaCl + 10 mM imidazole + 2 mM dithiothreitol (DTT) (Buffer A). The lysed cells 
were then centrifuged at 16,000 rpm at 4°C for 30 minutes to obtain a clear crude lysate. 
The protein sample was loaded on to a Nickel Column 5 ml HisTrap FF (GE Healthcare 
Cat no. 17-5255-01), which had been equilibrated with Buffer A using the AKTA FPLC 
Amersham Pharmacia Biotech instrument. The column was then washed with 10 column 
volumes (CV) of Buffer A. The sample was then eluted with a three-step linear gradient 
using 20 mM Tris-HCl, pH 7.2 + 250 mM NaCl + 500 mM imidazole + 2 mM DTT 
(Buffer B): 10%B for 3 CV, 30% B for 6 CV, 50% B for 5CV, and 100% B for 20 CV. 
Fractions of 1.5 mL were collected and analyzed using SDS-PAGE. All fractions that 
contained the desired protein were pooled together into a dialysis membrane tubing 
(FisherScientific, Cat. #08-6670) and dialyzed in 50 mM sodium acetate, pH 5.2 + 2 mM 
DTT (2 L x 2) at 4 °C to remove the imidazole and excess salt. The dialyzed protein was 
then centrifuged at 4 °C (3500 rpm) for 10 minutes using the Beckman GPR Centrifuge 
to remove any precipitated products. The protein was then concentrated using the 
Amicon Ultra-15 Centrifugal Filter Units Regenerated Cellulose 10,000 NMWL Ultracel-
10k (Millipore, REF UFC901024). The concentrated protein was analyzed using SDS-
PAGE, and concentration was estimated using the BCA Protein assay kit (Pierce, Cat. 
#23227) and BioTek ELx808 plate reader. The final concentrated protein was then 
aliquoted, flash frozen in liquid nitrogen, and stored at -80 °C. 
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Activation of Nickel Purified AaSPVII Z/pET28a 
A separate nickel purification of AaSPVII (No Leader) Zymogen enzyme was done 
with same methods as described above (all steps, dialysis, and concentrating to 7 mL). 
Approximately half of the nickel purified AaSPVII (No Leader) Zymogen concentrate (in 
50 mM sodium acetate, pH 5.2 + 2 mM DTT) was transferred into dialysis membrane 
tubing and allowed to dialyze in 2 L 20 mM Tris-HCl, pH 7.2 + 10 mM CaCl2 with 
stirring using a magnetic stirrer in the cold room (4 °C). Samples of 20 μL volumes were 
collected for both SDS-PAGE analysis and BApNA assays every 15 minutes for a total of 
135 minutes. SDS-PAGE analysis was done with the collected time points and the 
BApNA assay was monitored for color change but not analyzed on the spectrophotometer 
for trypsin-like activity (qualitative assay). 
In Vitro BApNA Spectrophotometric Assay of Recombinant AaSPVII (No Leader) 
Zymogen 
  
The synthetic chromogenic substrate BApNA (Acros Organics, Cat. # AC227740010) 
was used to test for trypsin-like activity. Different concentrations of BApNA and a 
constant concentration of AaSPVII (No Leader) Zymogen enzyme were used to obtain a 
Michaelis-Menten saturation curve.67 Reactions were initiated with 50 or 100 nM of the 
nickel purified AaSPVII Z (No Leader) Zymogen enzyme into the master mix and the 
absorbance at 405 nm was monitored using the Hewlett Packard (HP) 5452A Diode 
Array spectrophotometer as a function of time. Reaction rates were determined from the 
linear portions of the absorbance at 405 (A405) versus time plots using the extinction 
coefficient (ε 405nm) 8.80 mM-1*cm-1.  Each concentration was done in triplicate. Steady-
state conditions were set to help determine the kinetic parameters of the wild-type 
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AaSPVII enzyme. The results obtained from the spectrophotometer for each 
concentration was fit into the Michaelis-Menten equation and statistically analyzed using 
GraphPad Prism statistical software package (Version 5.0b for MAC OS X, GraphPad 
Software Inc). 
Site-Directed Mutagenesis of the Propeptide Cleavage Site and Active Site of 
AaSPVII 
 
Specific primers were designed with point mutations, in order to mutate the arginine 
at the propeptide cleavage site (see Figure 3) and the serine at the active site to alanine, 
following the guidelines from the QuikChange XL Site-Directed Mutagenesis Kit 
(Agilent Technologies, Cat. #200516). The arginine cleavage site was predicted to be the 
site of activation67 and the serine residue at the active site was predicted using ExPASy 
Prosite – Scan Prosite Tool (http://prosite.expasy.org/scanprosite/). The codon coding for 
arginine was changed from CGT to GCT to code for alanine. The codon coding for serine 
was changed from TCC to GCG to code for alanine (Table 5). Mutagenesis of the 
AaSPVII Z/pET28a plasmid was done with the purchased primers and following the 
methods described in the QuikChange XL Site-Directed Mutagenesis Kit, with the 
following changes. The annealing temperature was set to 60 °C and the elongation time 
was set to 7 minutes for each cycle for a total of 18 cycles. Super optimal broth (SOC) 
outgrowth medium (New England BioLabs, Cat. #B9020S) was used instead of NZY+ 
broth. After the one hour incubation, the 500 μL sample was pelleted and then 400 μL of 
the supernatant was removed. The pellet was resuspended with the remaining 100 μL and 
then plated onto an LB + kanamycin (30 μg/ml) agar plate. Overnight culture and 
isolation were done as described above. Mutations at these sites were confirmed through 
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DNA sequencing. The mutants were transformed into T7 SHuffle, and small-scale 
bacterial growth experiments were conducted as described above. The cells were induced 
and grown for a total of 28 hours, and 1 mL samples were collected at different time 
points. 
Table 5. Mutagenic Primers of AaSPVII. Point mutations were introduced at the arginine 
propeptide cleaving site and the active site serine. 
 
Protease  Primer                      Primer Sequence                            Tm (°C) 
AaSPVII – 
Zymogen 
AaSPVII-Mut-
R to A-Fwd 
5’-AAT AGC CGC ACT TCC GGC GGT GCT GTC GTC 
GGC GGT TAT GAA GT-3’ 91.82 
AaSPVII - 
Zymogen 
AaSPVII-Mut-
R to A-Rev 
5’-ACT TCA TAA CCG CCG ACG ACA GCA CCG 
CCG GAA GTG CGG CTA TT-3’ 
91.82 
AaSPVII -
Zymogen 
AaSPVII-Mut 
StoA-Fwd New 
5’ –TGC CAG GGT GAT GCG GGT GGT CCA TTG– 3’ 80.79 
AaSPVII -
Zymogen 
AaSPVII-Mut 
StoA-Rev New 
5’ –CAA TGG ACC ACC CGC ATC ACC CTG GCA– 3’ 80.79 
    Bold and underlined are the mutated codons of the selected sites. 
    Melting temperature calculated using NetPrimer. 
 
Results 
 
The presence of the leader sequence was hypothesized to lower expression levels of 
AaSPVII, as this was seen in other published articles as well.72,73 The designed primers 
were made specifically to remove the leader sequence and to facilitate cloning of the gene 
into the pET28a vector system to exploit the N-terminal His6-tag feature. The poly-A tail 
was added at the 5’-ends of each primer to improve cleaving efficiency of the restriction 
enzymes as it has been known that restriction enzymes have difficulty cleaving the 
recognition sites if they are located near or extremely near the 5’-ends.77 The primers 
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were purchased from Elim Biopharmaceuticals, Inc. and successfully worked in DNA 
cloning. The gene of interest was calculated to have 764 base pairs (bp) and, after PCR 
amplification, was shown to align with the DNA molecular weight ladder.  
The expression of the wild-type AaSPVII Zymogen in pET28a was carried out in 
both BL21 (DE3) and T7 SHuffle competent cells to confirm improved protein 
expression. The BL21 (DE3) cells were grown at 37°C and found to have improved 
expression without the leader sequence67 but failed to yield soluble protein (Figure 4). 
This was expected, as the disulfide linkage is crucial for proper protein folding and 
activity, which is impossible to form in bacterial systems due to their reducing 
environment74,76,78; this becomes arduous if soluble active enzyme is needed.  
 
Figure 4. SDS-PAGE analysis of AaSPVII Z/pET28a transformed in BL21 (DE3) 
competent cells stained in SimplyBlue. Molecular weight of the AaSPVII (No Leader) 
Zymogen protein was calculated to be 28.7 kDa, running near the 30 kDa band on the 
prestained protein ladder (ThermoScientific, Cat. #PI-26616). Total protein (T) was 
shown to be the highly expressed over 4 hours after 0.1 mM IPTG induction. Soluble 
protein (S) was not observed, revealing that the desired gene was expressed in insoluble 
form. Lane numbers represent time in hours.  
  (hrs.)      MW   T0      T1     T2      T3    T4      S0     S1     S2     S4
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We therefore turned to the BL21 (DE3) derivative known as T7 SHuffle, which contains 
mutations that create a more oxidizing environment in the cytoplasm. These competent 
cells also contain DsbC, a protein that helps with proper folding of disulfide bonds in the 
recombinant enzyme.76 Induction by IPTG in these bacterial strains led to soluble 
expression of the desired AaSPVII (No Leader) Zymogen of interest (Figure 5). When 
compared to the insoluble expression in BL21 (DE3), the T7 SHuffle expression resulted 
in soluble, properly folded AaSPVII, but also initial evidence of possible autocatalysis. 
The His-tag in gel stain (which specifically binds to His6-tagged enzymes) revealed a 
decrease in intensity over time (after induction) of AaSPVII grown in T7 SHuffle cells. 
This may suggest cleavage of the N-terminal His6-tag (Figure 5A). Once visualized with 
the His-tag stain, the same gel was stained with SimplyBlue to allow visualization under 
white light and comparison of expressed AaSPVII between the two stains. From both 
stained gels, the presence of three total bands appear with a band near the 30 kDa marker 
(AaSPVII No Leader Zymogen with the His6-tag approximately 28.7 kDa), and 
interestingly, the molecular weight of each species decreases, but the intensity compared 
to the rest of the proteins is higher. To test if any trypsin-like activity was present, a 
preliminary BApNA assay was set using the individual crude lysates obtained from the 
time point samples collected from the T7 SHuffle growth experiments. Surprisingly, 
trypsin-like activity increased over time (after induction), with maximal activity observed 
at the 18th hour of expression and gradually decreasing afterwards (Figure 6). 
 
33 
 
 
 
Figure 5. SDS-PAGE analysis of solubly expressed AaSPVII (No Leader) Zymogen 
expressed in T7 SHuffle competent cells, induced with 0.1 mM IPTG, grown for 28 
hours at 23 °C. Multiple species can be observed in both gels and may be suggesting 
auto-activation of the protease. Molecular weight of the AaSPVII Zymogen was 
calculated to be 28.7 kDa (red arrow). The no His6-tagged “Inactive” protease was 
calculated to be 26.8 kDa (yellow arrow). The mature protease was calculated to be 24.1 
kDa (green arrow). All predicted molecular weight calculations were done using 
ExPASy. A) Gel visualized with His-tag in gel stain. The intensity of the AaSPVII (No 
Leader) Zymogen enzyme can be seen fading as expression time increases, which may 
suggest that the enzyme is losing the N-terminal His6-tag. B) The same gel used in A was 
stained with SimplyBlue. The dominant expressed AaSPVII (No Leader) Zymogen 
species is over-expressed in the T = 4 and 8 hour samples, but as time increases, two new 
over-expressed species can be clearly seen. These results indicate the possibility of auto-
activation. Lane numbers represent time in hours. 
 30 
 25 
M
o
le
cu
la
r 
W
e
ig
h
t 
M
ar
ke
r 
(k
D
a)
 
A
) 
B) 
     MW  S0     S4    S8   S10  S15  S18  S20   S24  S26   S28   (hrs.) 
            MW   S0    S4     S8   S10  S15  S18  S20  S24   S26  S28 
 30 
 25 
M
o
le
cu
la
r 
W
e
ig
h
t 
M
ar
ke
r 
(k
D
a)
 
A) 
  (hrs.) 
34 
 
 
Figure 6. BApNA activity of AaSPVII Z/pET28a crude lysate. BApNA was used as a 
substrate to detect trypsin-like activity. From the collected time points, peak activity is 
observed at the 18th hour of expression and begins to decline post-18 hours. No 
significant activity is observed until after 10 hours of expression and growth. 
 
 After several small-scale bacterial growth experiments, we discovered that there are 
certain time points where the 28.7 kDa band was present before the other lower 
molecular weight species appeared. The maximal expression of the putative zymogen 
form was discovered to be intact until the 6th hour of expression and then visible auto-
cleavage occurs (data not shown). Because we are hypothesizing that the N-terminal 
His6-tag is being cleaved (Figure 5A) and there is no observed trypsin-like activity 
between 4-8 hours using the BApNA assay (Figure 6), we decided to collect cell paste for 
purification from the large-scale bacterial growth at 5 hours post-induction (Figure 7).  
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Figure 7. Large-scale bacterial expression of AaSPVII Z/pET28a transformed in T7 
SHuffle E. coli competent cells. Calculated molecular weight of AaSPVII (No Leader) 
Zymogen is 28.7 kDa. The cells were grown at 30 °C until OD600 ~0.5-0.8, induced with 
0.1 mM IPTG, and grown for 5 hours at 23 °C. A single band near the 30 kDa marker is 
increasing over time in both the total and soluble samples. Lane numbers represent time in 
hours. 
 
 To purify N-terminally His6-tagged AaSPVII (No Leader) Zymogen enzyme, 
multiple HisTrap FF Nickel purifications were attempted. As seen in Figure 5, 
autocatalyzed AaSPVII would pose a problem and not bind to the Nickel column due to 
the loss of the desired N-terminal His6-tag. Therefore, we hypothesized that by stopping 
the expression at the 5th hour and collecting the cell paste, we would be able to purify 
intact AaSPVII Zymogen, only if proper conditions are set. Unfortunately, trypsins have 
been shown to have broad maximal pH ranging from 7 to 9 for activity79. Regardless, the 
initial attempt was done with buffers at physiological pH (20 mM Tris-HCl, pH 7.2 + 
10mM CaCl2) to observe if it was possible to purify intact zymogen without changing the 
buffer conditions. As seen in Figure 8A, for purified AaSPVII, after dialysis and 
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concentration, a small band near the 25 kDa marker is observed, suggesting that the 
mature protease (24.1 kDa) is present and that it may be auto-degrading due to the 
presence of many other lower molecular weight protein species. In order to slow or 
inhibit this process, we attempted to add 2 mM dithriothreitol (DTT) to the purification 
and dialysis buffers to partially reduce disulfide bonds and minimize auto-degradation of 
the protease.67 As seen in Figure 8B, auto-digestion and full activation of the protease 
was slowed as the presence of the 26.8 kDa (no His6-tagged zymogen AaSPVII) and 24.1 
kDa (mature AaSPVII) bands were more pronounced compared to Figure 8A, and the 
concentration of degraded products were not as prominent. Because of this, and the fact 
that we were able to purify intact AaSPVII Zymogen (Figure 8C), we determined that 
simply adding DTT to the dialysis buffer was not enough to prevent activity and 
degradation. Therefore, we decided to alter the pH of the dialysis buffer. The purification 
buffers still contained 2 mM DTT, however, the dialysis buffer was changed to 50 mM 
sodium acetate, pH 5.2 + 2 mM DTT. As seen in Figure 8C, auto-activation and auto-
digestion was prevented, thus obtaining intact AaSPVII Zymogen. 
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Figure 8. Post-dialysis concentrate of three separate nickel purified AaSPVII Zymogen 
preparations. A) Dialysis was done in 2 L 20 mM Tris-HCl, pH 7.2 + 10 mM CaCl2 
(buffer exchanged twice and set at 4 °C). B) Dialysis was done in 20mM Tris-HCl, pH 
7.2 + 10 mM CaCl2 + 2 mM DTT (buffer exchanged twice and set at 4 °C). C) Dialysis 
was done in 50 mM sodium acetate, pH 5.2 + 2 mM DTT (buffer exchanged twice and 
set at 4 °C). All samples were concentrated after dialysis and analyzed using SDS-PAGE 
and Simple blue stained. All concentrations above are in micrograms, μg. 
 
To determine the activation of AaSPVII Zymogen, nickel purification of the AaSPVII 
was repeated, but after dialysis in sodium acetate buffer, 3.5 mL of the concentrated 
protein was dialyzed in 20 mM Tris-HCl, pH 7.2 + 10 mM CaCl2. Samples were taken at 
 30 
 25 
M
o
le
cu
la
r 
W
e
ig
h
t 
M
ar
ke
r 
(k
D
a)
  
A
) 
 30 
 25 
 30 
 25 
A) B) 
C) 
38 
 
different time-points and analyzed via SDS-PAGE and BApNA to determine if the 
protease was active prior to buffer exchange (Figure 9). SDS-PAGE showed consistent 
intensity of the 24.1 kDa “mature” protease band. This was also supported by the 
observed auto-activation and auto-degradation of the protease (Figure 9A), with no 
observable differences in BApNA cleavage over time (Figure 9B). It may be possible that 
there was not enough BApNA substrate compared to the amount of AaSPVII suggesting 
that the protease may prefer to cleave itself and not BApNA.   
 
Figure 9. Activation attempt of nickel purified AaSPVII Zymogen by buffer exchange 
from sodium acetate pH 5.2 to Tris-HCl pH 7.2. Activation and auto-degradation of the 
protease was achieved prior to buffer exchange. A) Band(s) can be seen between the 30 
or 25 kDa markers, however, due to the thickness of the band, it may be either the 26.8 
no His6-tagged “inactive” or the 24.1 kDa “mature” protein. B) Qualitative BApNA assay 
to check trypsin-like activity, which is nearly constant in all samples. Lane numbers 
represent time in minutes. 
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 Rascón et al. measured trypsin-like activity of AaSPVII and determined initial kinetic 
parameters using BApNA as the substrate.67 We wanted to replicate these steady-state 
kinetic parameters for the nickel purified AaSPVII Zymogen (Figure 8C). We 
hypothesized that the activation of the protease should be possible when transferring the 
zymogen into a buffer environment with a physiological pH. Therefore, we set reactions 
assuming steady state conditions, using 20 mM Tris-HCl, pH 7.2 + 10 mM CaCl2 and 
BApNA as a substrate, as described in Rascón et al. (2011).67 However, despite adding 
excess amount of BApNA, the reaction rates were zero (with no detectable activity) and 
very similar across all concentrations (data not shown).  
 Due to the autocatalytic nature of AaSPVII, site-directed mutagenesis was performed 
to introduce point mutations to the wild-type AaSPVII enzyme at the arginine in the 
propeptide region (Figure 3) and the serine at the active site in order to alter this observed 
activity. After predicting the position of the arginine (R38) in the propeptide region67 and 
the serine (S219) in the active site using the ExPASy Prosite – Scan Prosite Tool, 
mutations were made to alter the selected amino acids residues into an inert alanine80 in 
order to give insight into autocatalysis and prevent auto-activation of AaSPVII. The 
mutants were induced and grown like wild-type, and as seen in Figure 10, the AaSPVII 
R38A mutant expression resulted in possible loss of the N-terminal His6-tag, despite the 
propeptide region (the region that needs to be cleaved for full activation) being mutated. 
Figure 10A is the His-stain gel of samples collected from the small-scale expression 
experiment, which shows the disappearance of the N-terminally His6-tagged AaSPVII 
R38A mutant over time and appearance of a second band. It is important to note that 
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there was no third band present as seen in Figure 5 for wild-type AaSPVII (the third band 
being the active mature form). A preliminary BApNA assay repeated for these mutant 
samples revealed that there was no trypsin-like activity (data not shown). We 
hypothesized that the second species observed in Figure 10A is the no His6-tagged 
AaSPVII R38A zymogen mutant. As for the AaSPVII S219A mutant, expression resulted 
in a single band (Figure 11). This reveals the importance of the serine residue at the 
active site for AaSPVII function, as auto-activation and auto-digestion was prevented. 
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Figure 10. SDS-PAGE analysis of solubly expressed AaSPVII (No Leader) R38A 
Z/pET28a transformed in T7 SHuffle competent cells. Bacteria were grown at 23 °C, 
induced with 0.1 mM IPTG and allowed to grow for 28 hours. Two prominent species 
can be observed in both gels and may be suggesting auto-activation of the protease. 
Molecular weight of the AaSPVII mutant was calculated to be 28.7 kDa. The no His6-tag 
“Inactive” protease was calculated to be 26.8 kDa. A) Gel visualized with His-tag in gel 
stain. The intensity of the N-terminally His6-tagged AaSPVII mutant can be seen fading 
as expression time increases, which may suggest that the enzyme is losing the N-terminal 
His6-tag.  B) The same gel used in A was stained with SimplyBlue. The dominant 
expressed AaSPVII mutant species is over-expressed in the T = 4 and 8 hour samples, but 
as time increases, a new over-expressed species can be clearly seen. These results 
indicate the possibility of auto-activation, but not into its fully active mature state as seen 
in the wild-type AaSPVII (Figure 5). 
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Figure 11. SDS-PAGE analysis of solubly expressed AaSPVII (No Leader) S219A 
Z/pET28a transformed in T7 SHuffle competent cells. Bacteria were grown at 23 °C, 
induced with 0.1 mM IPTG and allowed to grow for 28 hours. Only one prominent 
species can be observed in both gels suggesting no auto-activation of the protease. 
Molecular weight of the AaSPVII mutant was calculated to be 28.7 kDa. A) Gel 
visualized with His-tag in gel stain. The intensity of the AaSPVII mutant band can be 
seen increasing as expression time increase, suggesting no loss of the N-terminal His6-
tag. B) The same gel used in A was stained with SimplyBlue. The expressed AaSPVII 
mutant species increases over time. These results indicate the presence of the mutant 
AaSPVII Zymogen that is unable to undergo autocatalysis. 
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Discussion 
 Previous expression experiments failed to yield sufficient soluble wild-type zymogen 
and mature AaSPVII protein for biochemical characterization.67 One of the major issues 
was the improper formation of the disulfide bonds due to the reducing environment of the 
BL21 (DE3) and Rosetta 2 (DE3) E. coli cells.67,71,74,76 Despite the fact that these cells are 
designed with the T7 expression system in order to enhance protein expression using pET 
vectors, the environmental cellular conditions are not optimal for proper expression and 
folding of midgut serine proteases. By switching to SHuffle T7 competent cells, which 
are derivatives of BL21 (DE3), the cells are more compatible for expression of mosquito 
proteases due to a more oxidizing environment.76 With these cells, we were able to 
successfully express soluble inactive and active forms of AaSPVII (Figure 4 and 5). In 
addition, the leader sequence (Figure 3) was removed from the gene, as it has been shown 
that the deletion of the putative signal sequence can aid in increasing protein expression 
by promoting thermodynamic stability and decreasing propensity for aggregation.72,73  
 The T7 SHuffle E. coli cells were able to provide the necessary environment and the 
DsbC protein to aid in disulfide bond formation and proper protein folding. This change 
led to the unexpected auto-activation of AaSPVII (Figure 5 and 6), which was not 
reported by Rascón et al. (2011).67 For their studies, an AaSPVII construct was 
engineered with a pseudo peptide region containing an enterokinase cleavage site 
(AaSPVII-Mek).67 According to the authors, this construct was designed to improve 
expression and to allow activation in vitro by using commercially available enterokinase 
(Figure 3), as it is unknown whether this enzyme and other midgut proteases are 
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autocatalytic.67 From the growth experiments of AaSPVII (No Leader) Zymogen/pET28a 
in SHuffle T7 cells, three distinct species can be observed. A visible band near the 30 
kDa MW marker (indicative of the zymogen AaSPVII species ~28.7 kDa) is initially 
present, followed by two other protein species appearing over time after induction. At the 
8th hour after induction, the presence of a second species at around 26.8 kDa might be 
indicative of the no His6-tag “inactive” AaSPVII Zymogen. Several supportive 
experiments were carefully analyzed to arrive at this hypothesis. As seen in Figure 5B, 
the His-stain clearly shows the disappearance of the His6-tagged AaSPVII Zymogen 
suggesting that the N-terminal poly His6-tag may be getting cleaved through possible 
autocatalysis of AaSPVII. However, full activation is not immediately observed. A 
second protein species in Figure 5B, which seems to be around 26.8 kDa, might be the 
zymogen without the N-terminal His6-tag. This is based on the presence of the thrombin 
cleavage site that is located between the N-terminal poly His6-tag and the NdeI restriction 
site on the pET28a vector.81,82 The thrombin site was included in the vector because the 
thrombin enzyme is known for its high proteolytic specificity, and therefore is a valuable 
biochemical tool to be exploited for cleaving off the fusion/purification tags that are 
normally included in linker regions of recombinant fusion protein constructs.83 Thrombin 
recognizes the cleavage site Leu-Val-Pro-Arg-Gly-Ser where it selectively cleaves 
between the Arg and Gly residues, even with the proline residue next to the Arg site.83 
Because AaSPVII has been identified as a classical trypsin66,67, and because, trypsins do 
not readily cleave peptides if a proline precedes an Arg residue69,70, we were surprised 
that this second species might be the product of cleavage at the thrombin cleavage site. 
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Subsequently, in collaboration with Prof. Anthony O’Donoghue at the University of 
California of San Diego, nickel purified mature AaSPVII was tested against 7-amino-4-
methylcoumarin (AMC)-based peptide substrates to gain initial insight into AaSPVII 
substrate specificity. These AMC-based substrates are important fluorogenic compounds 
used to probe proteolytic activity and specificity of proteases with unknown functions.84 
For these experiments, 2 nM AaSPVII was incubated with 20 μM of each substrate (in 20 
mM Tris-HCl. pH 7.4 + 100 mM NaCl + 10 mM CaCl2 + 0.01% Tween-20) and the 
maximal velocity (relative fluorescence units per second) measured and reported (Figure 
12). Surprisingly, using one of the AMC-based substrates (Boc-Ala-Gly-Pro-Arg-AMC) 
that is similar to the thrombin cleavage site, AaSPVII showed higher activity than both 
AaSPVI (another midgut late phase protease) and the porcine trypsin control (Figure 12). 
Additionally, alanine-scanning mutagenesis was used to probe its catalytic role and 
function80 by mutating R38 in the propeptide cleavage site and S219 in the active site to 
an inert alanine.  The auto-activation of AaSPVII was completely prevented due to the 
S219A mutation (Figure 11) and, from preliminary BApNA assays, no trypsin-like 
activity was observed (data not shown). Further evidence that the inactive wild-type 
AaSPVII Zymogen is cleaving the N-terminal His6-tag at the thrombin cleavage site 
comes from the R38A point mutation. This mutation was used for the expression of both 
the zymogen with the His6-tag and zymogen without the His6-tag, inhibiting full auto-
activation as no trypsin-like activity was observed in the in vitro spectrophotometric 
BApNA assays (Figure 10). Initial experiments have established AaSPVII to have 
trypsin-like activity, but unlike classical trypsins, this enzyme is able to cleave at an Arg 
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residue that is preceded by a Pro. In addition, there is a possibility that the “inactive 
zymogen” may not truly be inactive if the R38A mutant resulted in loss of the His6-tag. 
The S219A mutant did not lose the tag indicating that the bacterial cells are not 
producing an enzyme with this type of specificity. 
   
Figure 12. Fluorogenic assay of 7-amino-4-methylcoumarin (AMC)-based substrates 
with nickel purified mature AaSPVI and AaSPVII. A variety of AMC-based substrates 
were used to randomly test for activity and specificities of each protease.  A working 
stock of 10 μM protease was made in 20 mM citrate phosphate, pH 5.0 + 100 mM NaCl. 
The 10 μM was diluted to 2 nM in 20 mM Tris-HCl, pH 7.4 + 100 mM NaCl + 10 mM 
CaCl2 + 0.01% Tween-20 assay buffer. A 25 μL volume of the solution reacted with 25 
μL of each AMC-based substrate in triplicate. Porcine trypsin was used as a control 
trypsin. A 1 nM solution of AaSPVI and AaSPVII had approximately the same cleaving 
efficiency as 40 nM solution of porcine trypsin when Z-Phe-Arg-AMC was used as the 
substrate. The data is reported as the maximal velocity (RFU/sec) measured over 20 
points in 60 seconds for each reaction. 
          
 The third band observed in Figure 5 is hypothesized to be the active “mature” 
AaSPVII, as it correlated with the calculated 24.1 kDa molecular weight of the active 
species. In addition, the presence of the band (after induced expression) correlated in time 
with BApNA activity, especially reaching maximal activity at the 18th hour post-
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induction (Figure 5 and 6). These results were not too surprising, especially since 
trypsinogens in vertebrates have an enteropeptidase site (a region of repeating aspartic 
acid residues, followed by a lysine) at the propeptide region that allows enteropeptidases 
to regulate the activation of trypsin.51 However, trypsinogens in Ae. aegypti lack these 
repeated residues before the arginine, and therefore active trypsin may be produced from 
auto-activation. This is also supported by the fact that there has been no confirmed 
enteropeptidases found in the mosquito.51 
 Multiple purification attempts of N-terminally His6-tagged AaSPVII Zymogen were 
conducted to determine the effect of buffer conditions on the auto-activation of AaSPVII. 
Previously, only the artificially engineered Mek form of the midgut serine proteases was 
expressed in insoluble form and purified using denaturation/refolding techniques.67 For 
this thesis work, cell paste containing solubly expressed N-terminally His6-tagged 
AaSPVII Zymogen was collected at the 5th hour post-induction to obtain only the intact 
zymogen. A HisTrap FF nickel column was used due to histidine’s strong interaction 
with the immobilized transition metal ion matrices where histidine from the recombinant 
enzyme can readily form coordination bonds.85 This is beneficial since the N-terminal 
poly-His6-tag in the pET28a vector can bind to the nickel matrix and then be eluted using 
an increasing concentration of imidazole.85 Initial attempts used 20 mM Tris-HCl, pH 7.2 
+ 10 mM CaCl2 as the dialysis buffer after nickel purification, despite the fact the 
optimum pH for trypsin activity is near physiological pH.69,70,79 After concentrating and 
SDS-PAGE analysis, the protein was revealed to be heavily auto-degraded and still active 
(Figure 8A). Addition of 2 mM DTT slowed down autocatalysis and auto-degradation 
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(Figure 8B), as a mild concentration of DTT has shown to help create a mild reducing 
environment to partially misfold the protein of interest and minimize protease activity.67 
Auto-activation and auto-digestion of the protein was not observed after dialysis of the 
pooled fractions in 50 mM sodium acetate, pH 5.2 + 2 mM DTT. This is thought to be 
due to the pH change, going from 7.2 to 5.2 (Figure 8C). It is important to note that 
regardless of DTT being added to the purification buffers, the isolated fractions prior to 
dialysis were all observed to be intact, based on SDS-PAGE analysis. 
 The auto-activation of AaSPVII may be concentration-dependent because fractions 
collected from nickel purification shows intact AaSPVII Zymogen, but only after we 
concentrate the pooled fractions do we see auto-activation and digestion (Figure 8A). 
This is not too surprising because trypsin activation and auto-degradation is very 
sensitive to the concentration of the active form of trypsin present.86 After activation of 
trypsin, the active form can immediately activate all other trypsinogens, and therefore 
create an escalating chain reaction.86 This concentration-dependent auto-activation, may 
explain why the in vitro spectrophotometric assay using BApNA and the AaSPVII 
Zymogen form resulted in insignificant activity of the trypsin (data not shown). The 
nanomolar concentration of enzyme was too low and failed to undergo autocatalysis. 
 Since we hypothesized that AaSPVII was concentration-dependent, we decided to 
concentrate the isolated zymogen in 50 mM sodium acetate, pH 5.2 + 2 mM DTT and 
attempt to activate it by buffer exchanging into 20 mM Tris-HCl, pH 7.2 + 10 mM CaCl2. 
Unfortunately, as seen in Figure 9, partial auto-activation occurred prior to buffer 
exchange. The auto-activation was most likely initiated during the concentration step, but 
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it was discovered that the sodium acetate stock used for this experiment was at pH 9.4 
and not pH 5.2. The pH value is important because trypsins have broad maximal activity 
at pH ranges from 7 to 979, therefore, this allowed for auto-activation and auto-
degradation to occur. 
 The N-terminal His6-tagged AaSPVII protein was solubly expressed successfully 
after using the SHuffle T7 bacterial cells as confirmed by SDS-PAGE. However, the 
overexpression of this protein in bacteria led to auto-activation and auto-degradation over 
time after induction as observed from both SDS-PAGE and BApNA activity assays 
(Figure 5 and 6). Even after expressing and nickel purifying the N-terminally His6-tagged 
AaSPVII Zymogen, the enzyme auto-activated after dialyzing and concentrating in the 
optimal pH 7.2 buffer conditions. To prevent auto-activation of the enzyme, mutation at 
the Arg propeptide region (Figure 3) to an Ala resulted in the loss of the N-terminal His6-
tag, which indicates the possibility that the “inactive zymogen” may not be truly inactive. 
The bacterial cells used to express the wild-type and mutant forms of AaSPVII do not 
express an enzyme that cleaves at the thrombin cleavage site otherwise the S219A mutant 
would have more than one band observed during expression (Figure 11). Based on initial 
pepride fluorgenic AMC substrate activity assays, AaSPVII was shown to cleave arginine 
despite having a proline preceding it. In fact, the Pro-Arg-AMC substrate (Figure 12) is 
similar to the thrombin cleavage site on the N-terminal His6-tag linker on all of the 
AaSPVII constructs, indicating a preference for this type of sequence. Despite auto-
activation and loss of the N-terminal His6-tag of wild-type and R38A AaSPVII, we 
successfully isolated intact N-terminally His6-tagged AaSPVII (No Leader) Zymogen 
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using 50 nM sodium acetate, pH 5.2 + 2 mM DTT. Once the optimal activation 
conditions are found, the N-terminal His6-tagged AaSPVII (No Leader) Zymogen will be 
activated, purified, and used to obtain kinetic parameters using BApNA as the substrate 
and compared to previously published results.67 
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Chapter III  
Initial Biochemical Characterization of C-terminally His6-tagged AaSPVII 
Introduction 
 An unexpected and ultimately great result came from the expression and 
purification of wild-type AaSPVII Zymogen; under the right buffer conditions, the 
enzyme is autocatalytic (Chapter II). We were concerned that purification of the N-
terminally His6-tagged AaSPVII Zymogen would be deemed unsuccessful due to loss of 
the His6-tag. A possible solution to this problem is to move the N-terminal His6-tag to the 
C-terminus82,87,88 thereby allowing us to purify the mature (activated) form of the 
protease if isolation and activation of the zymogen is not possible. Placement of these 
poly-histidine affinity tags may alter the expression or solubility of the recombinantly 
expressed enzyme.89,90 Since not all recombinant enzymes behave the same upon addition 
of the His6-tag (at either termini), optimal placement of the affinity tag may be protein-
specific.89-93 For example, when the cleavable poly His6-tag was placed on the C-terminal 
end of the human serum transferrin enzyme, the enzyme’s ability to release iron at 
various pH conditions changed dramatically, while attachment at the N-terminus had no 
effect on the release rate.89 Another example of His6-tag having an effect on the 
recombinantly expressed enzyme was a study on the petrobactin biosynthesis gene asbF 
from Bacillus anthracis, which was shown to have the N-terminally His6-tag partially 
buried. Thus, the His6-tag may have interfered with protein folding and was not optimal 
for crystallization.93 Therefore, the pursuit of a C-terminal His6-tagged AaSPVII 
Zymogen as a novel construct was initiated, and we set out to investigate if this 
52 
 
attachment would alter the activity and/or expression of the protease and to compare the 
results with the solubly expressed N-terminal His6-tagged AaSPVII Zymogen.  
 In this chapter, the cloning, recombinant expression, purification, and the initial 
biochemical characterization of the C-terminal His6-tagged AaSPVII Zymogen construct 
using the pET29b vector82 will be discussed and its contrasted to AaSPVII in the pET28a 
vector. 
Methods 
Preparation of C-terminal His6-tagged AaSPVII Construct 
 The engineering of the C-terminal poly His6-tag construct was made by designing 
primers to facilitate the cloning of the AaSPVII Zymogen gene into the pET29b vector. 
The previous forward primer for wild-type AaSPVII was used (Table 6). The reverse 
primer was designed to remove the stop codons at the end of the gene and include the 
XhoI (CTCGAG) restriction cleavage site and a poly A-tail (Table 6). Cloning of 
AaSPVII Zymogen into the pET29b was done as described in Chapter II with the 
following modifications: 1) Instead of HindIII, used 1 μL of XhoI  (ThermoScientific, 
Cat. #ER0691) and 2) Ethanol precipitation was not done, instead, the digested AaSPVII 
PCR product and the digested/desphosphorylated pET29b vector were co-purified using 
the QIAquick Gel Extraction Kit and then ligated together overnight at 4 °C. 
Large-Scale Bacterial Overexpression and Purification 
 
 The AaSPVII (No Leader) Z/pET29b plasmid construct was expressed as described 
previously in Chapter II with the following modifications: 1) The cells were grown to 
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OD600 ~0.5-0.8 at 30 °C, then were induced with 0.1 mM IPTG and grown at 12 °C for 
44 hours, and 2) 5 mM DTT was added to Buffer A and B for FPLC purification.  
In Vitro BApNA Spectrophotometric Assay of Recombinant AaSPVII Z/pET29b 
 
 Nickel purified mature AaSPVII was used for a Michaelis-Menten steady-state 
kinetic experiment using the synthetic chromogenic substrate BApNA as described in 
Chapter II.  
Table 6. Designed Primers used for PCR Amplification and Cloning of C-terminal His6-
tagged Wild-Type AaSPVII Zymogen. Primers were purchased from Elim 
Biopharmaceuticals, Inc.  
 
Protease  Primer                      Primer Sequence                            Tm (°C) 
AaSPVII -
Zymogen 
AaSPVII-
Zym-pET-
Fwd 
5’–AAAAACATATGCTATCAACCGGATTCCATCCGC– 3’ 65.4 
AaSPVII -
Zymogen 
AaSPVII-C 
term His-
Rev 
5’–AAAAACTCGAGAACTCCACTGACTTCGGCCACC–3’ 65.0 
Poly-A tail used is in BOLD. 
Restriction sites used for cloning of the genes of interest are underlined. 
Start codons is italicized. 
Annealing temperature calculated using NetPrimer. 
 
Results 
 The cloning of AaSPVII into the pET29b vector system was done not only to purify 
the mature protease in the event of autocatalysis, but to also investigate if affinity tag 
placement may affect recombinant protein expression. The soluble expression of N-
terminally His6-tagged AaSPVII (No Leader) Zymogen was done at 23 °C (Chapter I). 
However, recombinant expression of the C-terminally His6-tagged AaSPVII (No Leader) 
Zymogen was done at 12 °C to allow for proper folding since we are unsure if changing 
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His6-tag placement will alter the properties of the enzyme.
94 This lower growth 
temperature should inhibit or slow down the auto-activation process, as was seen for the 
AaSPVII Z/pET28a construct. As seen in Figure 13, after induction with 0.1 mM IPTG, 
the AaSPVII Zymogen was slowly expressed over 44 hours. The molecular weight of 
AaSPVII Z/pET29b was calculated to be 27.6 kDa and the “active” no propeptide 
protease is 25.2 kDa. And based on the figure, the majority of the expressed species is the 
zymogen form (27.6 kDa), running near the 30 kDa marker, as desired. With the intact C-
terminal poly His-tag on AaSPVII, nickel purification was pursued. 
 
Figure 13. SDS-PAGE analysis of solubly expressed AaSPVII (No Leader) Z/pET29b 
transformed in T7 SHuffle competent cells. Bacteria were grown at 12 °C, induced with 
0.1 mM IPTG, and allowed to grow for 44 hours. Only one prominent species can be 
observed in the gel, which may suggest no auto-activation of the protease. Molecular 
weight of the AaSPVII Zymogen protein was calculated to be 27.6 kDa. The ‘active’ 
AaSPVII was calculated to be 25.2 kDa. Gel visualization with SimplyBlue stain. 
 
 Purification of the C-terminally His6-tagged AaSPVII (No Leader) Zymogen was 
repeated as performed with the wild-type N-terminally His6-tagged AaSPVII Zymogen 
described in Chapter II. Surprisingly, after dialysis in 50 mM sodium acetate, pH 5.2 + 2 
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mM DTT and concentration, the mature form of the protease was isolated. This was 
based on SDS-PAGE analysis and the presence of what seems to be auto-degradation 
products below the MW of the “active” AaSPVII protease (25.2 kDa) (Figures 14).  
 
Figure 14. SDS-PAGE analysis of nickel purified “active” mature AaSPVII. The mature 
protease was the final product observed after dialysis and concentration. The expected 
molecular weight of mature AaSPVII is 25.2 kDa. Several auto-degradation products are 
observed.  
 
 To determine if this purified AaSPVII is indeed active, trypsin-like activity was tested 
using BApNA as the substrate.67 The concentration of enzyme was selected to be 50 nM 
for the lower BApNA concentrations and 100 nM for the higher concentrations67 in order 
to maintain a 10-fold lower enzyme concentration compared to the lowest substrate 
concentration used95. Therefore, to obtain kinetic parameters, 50 nM active AaSPVII was 
used at each BapNA concentration in order to produce the Michaelis-Menten plot in 
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Figure 15. The kinetic parameters obtained were comparable to the results published by 
Rascón et al.67 (Table 2 and Figure 15). 
 
 
 
Protease* 
 
 
KM (BApNA) (μM) 
 
 
kcat (s-1) 
 
 
kcat/KM (mM-1 s-1) 
Specific Activity 
 (μmol min-1 (mg of 
protein)-1) 
AaSPVII 22.0±1.9 0.53 24.1 1.31 
 *Reaction conditions: 20 mM Tris-HCl, pH 7.2 + 10 mM CaCl2 at 23 °C. 
 All values were calculated from the mean of three reactions. 
 The produced Michaelis-Menten plot had an R2 value of 0.9639. 
 
Figure 15. Steady-state kinetic parameters of mature AaSPVII using BApNA as a 
substrate. AaSPVII at 50nM was reacted with an excess amount of BApNA to create the 
Michaelis-Menten plot. The kinetic parameters were determined using GraphPad prism. 
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Discussion 
 
 The C-terminally His6-tagged protease (AaSPVII Z/pET29b) construct was prepared 
to help alleviate the purification problem, and to investigate if the placement of the 
affinity tag would alter expression, folding, and/or activity.89,90,93,96  
 Proper folding and soluble recombinant protease expression in bacteria 
can vary due to the placement of the poly-histidine affinity tag (as mentioned in the 
Introduction), but also with growth temperature.85,94 As seen in Figures 5 and 13, the C-
terminally His6-tagged AaSPVII Zymogen was fully expressed until the 44
th hour (post-
induction) at 12 °C, while the N-terminally His6-tagged AaSPVII Zymogen was 
expressed earlier at the 6th hour (post-induction) at 23 °C. By lowering the growth 
temperature of the bacterial cells, the metabolism and protein expression machinery of 
the host cell is slowed to allow the protease to fold properly74, but to also slow the auto-
activation activity of the enzyme. Mammalian proteases in general have optimal activity 
at 37 °C97, and similarly these mosquito proteases are expected to function at the elevated 
temperature of the blood meal. However, since blood meal digestion is a relatively long 
process (between 30 to 40 hours), the temperature of the mosquito and the blood meal 
decreases to ambient levels98 and protease activity is unaffected. So, we hypothesized that 
if the temperature is reduced below the optimal ambient temperature (typically 23 °C), 
proteolytic activity should be minimized. Therefore, for the C-terminally His6-tagged 
AaSPVII Zymogen recombinant expression, the temperature was dropped to 12 °C. The 
lower temperature approach led to successful overexpression, but more importantly, 
slowed down auto-activation of the C-terminally His6-tagged AaSPVII for purification 
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(Figure 13). Comparing this expression with AaSPVII Zymogen/pET28a construct grown 
at 23 °C, the ideal proteolytic temperature of the midgut proteases, auto-autoactivation 
was clearly observed (Figure 5). Once the C-terminally His6-tagged AaSPVII Zymogen 
was expressed, the enzyme was nickel purified and dialyzed in sodium acetate buffer as 
was done with the N-terminally His6-tagged AaSPVII Zymogen. Unfortunately, after 
concentrating the dialyzed C-terminally His6-tagged AaSPVII Zymogen, the enzyme had 
autocatalyzed to the “mature” protease. This was attributed to the sodium acetate used 
during dialysis. The sodium acetate buffer was found to have a pH of 9.4, the pH of the 
salt dissolved in water before adjusting to pH 5.2 with acetic acid. Proper preparation of 
the buffer was not followed, leading to the result observed.  
 As mentioned, Rascón and associates determined steady-state kinetic parameters for 
active AaSPVII isolated from inclusion bodies (Table 2).67 This in vitro 
spectrophotometric assay using BApNA was repeated with purified N-terminally His6-
tagged AaSPVII Zymogen, but the assay failed to show any significant activity (data not 
shown). However, with the nickel purified C-terminally His6-tagged AaSPVII mature 
protease (Figure 14), the assays were repeated and are comparable to the steady-state 
kinetic parameters published.67 These results suggest that the AaSPVII enzyme in these 
experiments was solubly expressed and purified successfully, which had never been 
repeated since the AaSPVII Rascón et al. (2011) work.67 More importantly, however, 
placement of the His6-tag on the C-terminus did not have an effect on AaSPVII 
expression or activity, which will allow for further protease purification optimization and 
enzyme specificity assays.  
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Chapter IV 
 
Summary and Future Directions 
 
 The Ae. aegypti mosquito is an efficient biological vector, transmitting several viruses 
when the female mosquito acquires a blood meal.34,36,47 Digestion of blood meal proteins 
is required to complete the gonotrophic cycle35,36, and is highly dependent on midgut 
proteases. Therefore, it may be possible to inhibit these digestive enzymes with small 
molecule inhibitors to prevent the completion of the gonotrophic cycle, and therefore, 
potentially reduce the mosquito population and viral transmission.59,67 As seen in Figure 
2A, specific digestive enzymes were suppressed and were shown to have varying effects 
on the overall fecundity of the female Ae. aegypti mosquito. Additionally, diluted blood 
meals were fed to mosquitoes, and a significant reduction of eggs was observed (Figure 
2B), thus demonstrating how crucial protein blood meal digestion is for the egg laying 
process.59 With the reemergence of the YFV30,31, DENV38,40, CHIKV32,40, and ZIKV15,40, 
and the need for better control strategies, investigating the midgut serine proteases 
involved in the digestive process may prove to be a potential vector control strategy.59,67 
 The work presented in this thesis serves to re-evaluate the potential role of the late 
phase midgut serine protease AaSPVII that was previously characterized by Rascón et 
al.67. In this study, soluble expression of the AaSPVII Zymogen was not sufficient and 
had to be engineered with an artificial propeptide region containing an enterokinase site. 
Even then, however, expression was insoluble and denaturation/refolding techniques 
were utilized to obtain purified soluble protein.67 Interestingly, the isolated AaSPVII was 
shown to be biochemically different from AaSPVI despite being homologous to each 
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other.59,66 AaSPVI was shown to contribute to the majority of late-phase trypsin-like 
activity in the midgut, while AaSPVII had no significant effect59, despite both proteases 
cleaving the chromogenic trypsin-like substrate BApNA in vitro67 (Table 2). This raises 
the interesting question as to the specificity and functionality of AaSPVII, a question that 
warrants further studies to elucidate the role of AaSPVII in blood meal protein digestion. 
 Although Rascón and associates were successful at obtaining soluble AaSPVII using 
denaturation/refolding techniques, the refolding process is rigorous and has the potential 
to reduce protein yield.67,75 Two of the main issues regarding low protein yield are the 
presence of the leader (signal peptide) sequence (Figure 3) and the reducing environment 
of the competent bacterial cells used for protein expression, which prevents proper 
disulfide formation.76 Removal of the leader sequence has been shown to increase the 
yield of desired proteins.72,73 By designing specific leaderless primers for AaSPVII to 
facilitate cloning into the pET28a and pET29b vectors82, and by using bacterial cells with 
a more oxidizing cytoplasm76, we were able to successfully express and purify the 
zymogen and active mature forms of AaSPVII in soluble form (Chapters II and III).  
 The first construct (AaSPVII (No Leader) Z/pET28a) led to AaSPVII autocatalysis 
during expression with maximal trypsin-like activity detected at the 18th hour (post-
induction) (Figures 5 and 6). However, we did manage to purify the enzyme using a 
nickel column by collecting the cell paste at 5-6 hours post-induction (Figure 5) and 
altering the buffer conditions needed to prevent auto-activation and auto-digestion 
(Figure 8). AaSPVII has been classified as a classical trypsin enzyme59,66,67, but trypsins 
cannot cleave at an Arg residue with a Pro residue preceding it.69,70 However, AaSPVII 
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was shown to cleave an AMC fluorogenic substrate that contains a Pro-Arg sequence 
(Figure 12 and Chapter II). This proved to be slightly problematic since a thrombin 
cleavage site (Leu-Val-Pro-Arg-Gly) is engineered into the pET28a vector to facilitate 
removal of the His6-tag. AaSPVII was shown to prefer the thrombin cleavage site (Figure 
5), and during expression the enzyme was cleaving the His6-tag, which would not allow 
for nickel purification. 
 As an alternative, AaSPVII was cloned into the pET29b vector to yield a C-terminally 
His6-tagged enzyme in order to purify either the zymogen or mature form of the protease. 
Purification of the C-terminally His6-tagged AaSPVII resulted in isolation of the mature 
“active” form of AaSPVII (data not shown), even in the presence of sodium acetate, pH 
5.2 and the reducing agent DTT. However, it was later discovered that the sodium acetate 
buffer was at a pH of 9.4 because acetic acid was not added to lower the pH. We 
hypothesized that the N-terminally His6-tagged enzyme autocatalyzes only after removal 
of imidazole, NaCl, and DTT (dialysis step) and concentrated at the optimal pH 
conditions for activity (pH 7.2). The autocatalytic nature of the C-terminally His6-tagged 
AaSPVII has not been fully investigated. At this point, we are unsure if the enzyme is 
expressed as the active form or the zymogen form, but the final isolated product (after 
cell lysis, centrifugation, purification, dialysis, and concentration) is fully active. This 
conclusion is based on the steady-state kinetic parameters obtained from solubly purified 
AaSPVII, which is comparable to published results67 (Table 2 and Figure 15). In addition, 
the expression and purification approach described in this thesis has led to a much more 
efficient process of obtaining active AaSPVII enzyme.  
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 To better understand the autocatalytic mechanism of AaSPVII, we can focus on the 
N-terminally His6-tagged AaSPVII Zymogen, which was successfully purified in its 
inactive form (Figure 8C). A pH profile using various pH buffers (ranging from pH 4 to 
10) can be set to determine the best conditions for auto-activation and optimal protease 
activity. Once the mechanism of activation is determined, we can then compare the 
kinetic parameters between this construct and the active C-terminally His6-tagged 
AaSPVII protease, as well as to the Rascón et al. published data shown in Table 2.67  
 The work described in this thesis has laid the foundation to further investigate and 
biochemically study not only AaSPVII, but other midgut serine proteases as well. The 
specificity of AaSPVII is still unknown. However, in collaboration with Prof. Anthony 
O’Donoghue from UCSD, we hope to utilize the Multiple Substrate Profiling by Mass 
Spectroscopy technique to determine the proteolytic signature and specificity of 
AaSPVII. This technique is suitable for the identification of substrate specificity of exo- 
and endopeptidases.99 Therefore, as an immediate goal, we need to optimize the 
purification scheme to obtain homogeneous AaSPVII Zymogen and the mature active 
form for these studies. In addition, to further characterize AaSPVII, x-ray crystallography 
can be used to further understand the relationship between the three-dimensional 
structure of the enzyme and its biological activity. More importantly, these structural 
studies can then serve to help design inhibitors if these proteases prove to be suitable 
targets for vector control. Lastly, once the roles of AaSPVII and other midgut proteases 
in the blood meal protein digestion process are fully understood, it might be worth 
investigating the interaction of the enzymes with the viruses transmitted by the Ae. 
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aegypti mosquito. The first site of viral infection and replication in the mosquito is the 
midgut.100 Brackney and associates examined a knockdown of AaSPVI in vivo which 
resulted in an increase in infectivity of DENV-2 in the mosquito, suggesting that certain 
midgut serine proteases may play a role in regulating viral infectivity.101 Before 
mosquito-selective inhibitors can be formulated, further biochemical studies on these 
midgut serine proteases have to be completed in order to elucidate their specific roles in 
blood meal protein digestion, but also to determine if there is a host protease interaction 
network that increases viral infectivity in the mosquito. 
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